Expression Analysis announces grants for research into complex diseases

Expression Analysis, Inc., the industry’s leading provider of genomic services for clinical trials and research, announced today a family of grants focused on one unifying purpose: To accelerate research into complex diseases and aid researchers in unlocking biological mysteries.

Dedicated to a deeper understanding of human health and disease, the grant will award four deserving researchers access to Expression Analysis’ state-of-the-art services. Four grants will be awarded; two focusing on genome-wide association studies and two on follow-up to GWAS. Included in all four grants is data analysis through digenysis™ a proprietary analysis tool that simultaneously analyzes allelic and copy number variation, accomplishing in days what can typically take months.

“Genomic technologies play a key role in the diagnosis, treatment and management of complex diseases and, to effectively tackle diseases we need to encourage the best and brightest minds to take risks on novel ideas. Our grant initiative is designed to further research in efforts to identify genetic elements important to human health and disease,” stated Steve McPhail, CEO of Expression Analysis.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy